ONCBeiGeneFinished
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC) · Nonsmall Cell Lung Cancer, Stage IIIB · Nonsmall Cell Lung Cancer, Stage IV
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 272 (final count)
- Started
- Nov 16, 2021
- Main results expected
- Sep 4, 2024
- Fully finished
- Sep 4, 2024
- Results posted
- Sep 16, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS)
Measured over: From randomization up to the final efficacy analysis data cut-off date of 04 September 2024; Up to 33 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05014815 · record last updated 2025-09-16 · checked 2026-11-09 15:47 UTC